http://www.alliedminds.com/

"Allied Minds is an innovation company that forms, funds, manages and builds startups based on early-stage technology originating from U.S. universities and federally funded research institutions. We created a new business model for overcoming early-stage development gap between basic research and commercial development. Our investors are aligned with our vision that cutting-edge invention is an attractive, yet under-developed, asset class. We review numerous ideas but only select opportunities with potential to deliver outsized returns. We create subsidiaries led by seasoned management who know how to turn academic breakthroughs into commercial products and then take them to market. We provide our subsidiaries with capital resources, from seed to self-sustainment. Our aim is to promote growth, generate jobs, foster innovation and create societal benefit."

StockMarketWire.com
Allied Minds subsidiary Spin Transfer Technologies and Tokyo Electron have signed an agreement for a collaborative engineering programme for next-generation SRAM and DRAM-class ST-MRAM devices.

Allied Minds said the combination of STT's ST-MRAM technology and TEL's advanced PVD MRAM deposition tool would allow the companies to quickly develop processes for the highest density and endurance devices.

StockMarketWire.com
SciFluor Life Sciences, a subsidiary of Allied Minds, has announced positive top-line results of a phase 1/2 trial studying the treatment of 'wet' age-related macular degeneration patients with SF0166, the company's lead eye drop drug for back of the eye diseases.

The double masked phase 1/2 study assessed the safety, tolerability and preliminary efficacy of SF0166 in 42 evaluable subjects with neovascular (wet) AMD who were randomised 1:1 to self-administer an eye drop containing either a 2.5% or a 5% solution of SF0166 twice-a-day for 28 days.

It said the primary outcome measure of safety was clearly achieved with no drug-related serious adverse events observed in the study throughout the 28-day course of treatment as well as during the 28-day follow-up period.

Ocular adverse events were recorded in the treated eyes of 5 patients; all events were mild or moderate in severity, with one considered possibly drug-related.

Credit Suisse today reaffirms its neutral investment rating on Allied Minds PLC (LON:ALM) and cut its price target to 110p (from 175p).

2 years ago these were 450p a share now 50p.

bargain.